Thanks Robert.
I think this is the clinical trial:
http://clinicaltrials.gov/show/NCT02043678
Looks like it's a double blind trial where you may or may not get radium-223. All participants would get Zytiga and Prednisone.
Inclusion Criteria:
- Histologically or cytologically confirmed adenocarcinoma of the prostate
- Male subjects of age ≥ 18 years
- Prostate cancer progression documented by prostate specific antigen according to the Prostate Cancer Working Group 2 (PCWG2) criteria or radiological progression according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.
- Two or more bone metastases on bone scan within 4 weeks prior to randomization with no lung, liver, other visceral and/or brain metastasis.
- Asymptomatic or mildly symptomatic prostate cancer.
- Subjects who received combined androgen blockade with an anti-androgen must have shown PSA(prostate specific antigen) progression after discontinuing the anti-androgen prior to enrollment.
- Medical or surgical castration with testosterone less than 50 ng/dL (1.7nmol/L).
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
Exclusion Criteria:
- Prior cytotoxic chemotherapy for the treatment of CRPC, including taxanes, mitoxantrone and estramustine
- Any chronic medical condition requiring a higher dose of corticosteroid than 5 mg prednisone/prednisolone bid.
- Pathological finding consistent with small cell carcinoma of the prostate
- History of visceral metastasis, or presence of visceral metastasis detected by screening imaging examinations
- History of or known brain metastasis.
- Malignant lymphadenopathy exceeding 3 cm in short-axis diameter.
- Blood transfusion or erythropoietin stimulating agents prior 4 weeks of screening and during the whole screening period before randomization
- Imminent spinal cord compression based on clinical findings and/or magnetic resonance imaging (MRI). Subjects with history of spinal cord compression should have completely recovered
- Use of opiate analgesics for cancer-related pain, including codeine and dextropropoxyphene, currently or anytime during the 4- week period prior to randomization.